Belvedere Trading
PCVX icon

Belvedere Trading’s Vaxcyte PCVX Stock Holding History

Belvedere Trading’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,500
Closed -$286K – 998
2024
Q3 		$286K Sell
2,500
-2,400
-49% -$216K ﹤0.01% 277
2024
Q2 		$370K Buy
4,900
+1,500
+44% +$102K ﹤0.01% 236
2024
Q1 		$232K Buy
+3,400
New +$235K ﹤0.01% 301

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Belvedere Trading's PCVX Position: Q4 2024 in Review

Belvedere Trading sold out of Vaxcyte (PCVX) in Q4 2024, closing a stake of 2,466 shares — an estimated $282K sold.

Belvedere Trading first reported a position in PCVX in Q1 2024 and held it in 3 quarters. The position peaked at $282K in Q3 2024. 323 funds tracked by Wall St. Rank hold PCVX as of Q4 2024.

  • Belvedere Trading reported no remaining Vaxcyte position as of Q4 2024 after selling out during the quarter.
  • Belvedere Trading sold 2,466 Vaxcyte shares in Q4 2024, an estimated $282K.
  • Belvedere Trading first reported a position in Vaxcyte in Q1 2024 and held it in 3 quarters.
  • Belvedere Trading's Vaxcyte position peaked at $282K in Q3 2024.
  • 323 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2024.

Based on Belvedere Trading's 13F filing for Q4 2024, filed 31 Jan 2025.